Evidence map›Paper›PMID 38770814›Full record

ArticleBMJ global health2024

Lessons learnt from daily oral PrEP delivery to inform national planning for PrEP ring introduction for women in low-income and middle-income countries: a qualitative inquiry of international stakeholders.

Craig J Heck, Anita Dam, Kibret Yohannes, Justine Deacon, Katharine Kripke, Kathrine Meyers, Ohemaa Poku, Christopher Obermeyer, Sarah Wiant, Daniela Quigee and 5 more

Abstract read
In one paragraph

Article in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Craig J Heck *Columbia University Mailman School of Public Health, New York, New York, USA cjh2204@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-8138-6640
Anita DamUnited States Agency for International Development, Washington, District of Columbia, USA.
Kibret YohannesUniversity of Virginia School of Medicine, Charlottesville, Virginia, USA.
Justine DeaconCDC Foundation Inc, Atlanta, Georgia, USA.
Katharine KripkeAvenir Health, Takoma Park, Maryland, USA.ORCID http://orcid.org/0000-0001-8228-4577
Kathrine MeyersColumbia University Irving Medical Center, New York, New York, USA.
Ohemaa PokuNew York State Psychiatric Institute, New York, New York, USA.
Christopher ObermeyerThe Global Fund to Fight AIDS Tuberculosis and Malaria, Grand-Saconnex, Switzerland.
Sarah WiantColumbia University Irving Medical Center, New York, New York, USA.
Daniela QuigeeColumbia University Irving Medical Center, New York, New York, USA.
Martha LarsonFHI 360, Durham, North Carolina, USA.
Christine MalatiUnited States Agency for International Development, Washington, District of Columbia, USA.
Magdalena E SobieszczykColumbia University Irving Medical Center, New York, New York, USA.
Sergio Torres-RuedaLondon School of Hygiene & Tropical Medicine, London, UK.ORCID http://orcid.org/0000-0002-6335-6392
Delivette Castor *Columbia University Mailman School of Public Health, New York, New York, USA.

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Columbia Collaborative HIV/AIDS Clinical Trials UnitU01AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAMMER, SCOTT M · 2007 to 2011
$15.4M
Global HIV Implementation Science Research Training Grant RenewalT32AI114398 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Yael R Hirsch-Moverman · 2014 to 2026
$4.1M
NIAID NIH HHS T32 AI114398NIAID NIH HHS U01 AI069470NIAID NIH HHS UM1 AI069470
6 · The paper itself

Abstract

introductionSome African countries plan to introduce and scale-up new long-acting pre-exposure prophylaxis methods (LA-PrEP), like the monthly dapivirine vaginal ring (PrEP ring) and injectable cabotegravir. National costed implementation plans, roadmaps for successful product implementation, are often overlooked. International stakeholders engaged in oral PrEP planning, introduction and scale-up are an information resource of lessons learned to advise LA-PrEP planning. We consulted such international stakeholders and synthesised oral PrEP lessons to inform the development of a costed rollout plan template for LA-PrEP.

methodsFrom selected global health organisations (five international nongovernmental, four donor, four university/research and two multilateral), we interviewed 27 representatives based in America, Europe, Asia and Africa about strategic content and approaches for LA-PrEP policy, programming and implementation. We conducted a thematic analysis of the interview data for implementation considerations.

resultsFrom the consultations, we identified six implementation themes for LA-PrEP introduction and scale-up: (1) ethically increasing choice and avoiding coercion; (2) de-stigmatising PrEP by focusing on preference rather than risk-based eligibility; (3) integrating LA-PrEP into services that are more woman-oriented, couple-oriented and family-oriented, and providing private spaces for LA-PrEP delivery; (4) de-medicalising delivery of relatively safe products (eg, PrEP ring); (5) constructing multilevel, nuanced communication strategies to address measured and perceived product efficacy and effectiveness; and (6) devising product-agnostic, modular approaches to service delivery. Despite the widespread emphasis on integration, few stakeholders offered empirical examples of successful integration approaches and frameworks.

conclusionsLessons learnt from stakeholder participants suggest standardised and modular processes can improve efficiencies in LA-PrEP planning and implementation. Tiered communication strategies addressing product efficacy and effectiveness will improve clients' and providers' efficacy in making informed decisions. Integration is important for LA-PrEP delivery, but data on empirical integration approaches and frameworks is minimal: further research in this discipline is needed.

Indexed as

Developing CountriesHIV InfectionsPre-Exposure ProphylaxisQualitative ResearchAdministration, OralAnti-HIV AgentsContraceptive Devices, FemaleFemaleHumansAnti-HIV AgentsHealth policyHealth services researchHIVPrevention strategiesPublic Health

Identifiers

PMID38770814
PMCPMC11085820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.